FIG 2.

ADE mechanisms and assay validation for FcγR- and C1q-mediated ADE using VSV-EBOV and an EBOV glycoprotein-specific monoclonal antibody. Infectious titers of VSV-EBOV mixed with indicated concentrations of monoclonal antibody ZGP12/1.1 (27) were measured in (A) Vero E6/FcγRIIa cells, (B) Vero E6 cells in the presence of C1q, and (C) Vero E6 cells in the absence of C1q. The relative numbers of infected cells were calculated by setting the number of GFP-positive cells in the absence of the antibody to 100%. Dots and error bars indicate the means and standard deviations of triplicate wells, respectively. Right panels show schematics of the respective conditions.